iMDx reported a peer-reviewed study in Transplant International titled “Donor-Derived Cell-Free DNA as a Non-Invasive Readout of Activity Across the Rejection Continuum,” conducted by investigators at Heidelberg University Hospital and Charité – Universitätsmedizin Berlin. The multi-center analysis included 249 biopsy-matched kidney transplant patients from two cohorts and compared blood plasma dd-cfDNA with histopathology-derived rejection indices. The study found dd-cfDNA levels increased with graft inflammation, with the strongest associations in microvascular inflammation and antibody-mediated rejection. iMDx said its GraftAssure Combination Model score, which combines dd-cfDNA % and copies/mL, showed stronger correlations with four organ-health indices than percentage-only or absolute-only measures. The company said related data were previously presented at the World Transplant Congress in 2025, including a positive predictive value above 80% at 25% prevalence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130800PRIMZONEFULLFEED9671448) on March 13, 2026, and is solely responsible for the information contained therein.